Communiqués Eli Lilly and Company Mexican S.E.

Actions

LLY *

US5324571083

Produits pharmaceutiques

Cours en clôture Mexican S.E. 09/09/2026			Varia. 5j.	Varia. 1 janv.
19 025,00 ^MXN	+0,04%		-3,43%	-2,03%

01:24	L'administration Trump poursuit de nouveaux accords sur le prix des médicaments, selon Mehmet Oz	MT
09/09	Kura Oncology lance Caspian Therapeutics avec un financement de 50 millions de dollars	MT

Communiqués

01/09	Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference	PR
31/08	New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity	PR
31/08	Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases	PR
31/08	Peptides TIL Covers Emerging Retatrutide Data From Landmark Phase 3 Trials	AQ
28/08	AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI	PR
28/08	FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes	PR
27/08	Eli Lilly and Company - Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study	AQ
26/08	Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study	PR
18/08	Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of LTX-001 in Schizophrenia	AQ
12/08	Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market	PR
11/08	Lifespan Vision Ventures Leads Remedium Bio's Series A Financing	AQ
06/08	Eli Lilly and : 2025 Sustainability Data (Lilly 2025 Sustainability DataDownloadWorkbookFinal.xlsx)	PU
05/08	Eli Lilly and : Q2 2026 Lilly Press Release	PU
05/08	Lilly: Q2 Earnings Snapshot	AQ
05/08	Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress	PR
03/08	Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer	PR
23/07	Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C	PR
22/07	Lilly confirms date and conference call for second-quarter 2026 financial results announcement	PR
21/07	Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates	PR
16/07	Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions	PR
16/07	Pharmaceutical Method-Of-Use Claims After Teva v. Eli Lilly And In Re Xencor: Written Description, Enablement, And The Known-Compound Genus	AQ
09/07	/C O R R E C T I O N -- Eli Lilly and Company/	PR
01/07	Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios in Mainland China	AQ
26/06	Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy	PR
25/06	What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management	PR